Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB123667 + Bevacizumab vs Bevacizumab in First-Line Maintenance for Advanced Ovarian Cancer (MAESTRA 3)
NCT07797283Phase 3Not yet recruiting
- Sponsor
- Incyte
- Start
- Dec 2026
- Primary completion
- May 2032
01
Overview
A Phase 3 trial of INCB123667 in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Incyte. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
INCB123667
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT07797283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07797283.